Licochalcone D Clinical Trials

Size	Price	Qty
1mg	USD 147

Clinical Trials

Several clinical trials are investigating indications across Lyme disease, diffuse large B-cell lymphoma and other B-cell malignancies, cardiometabolic conditions including diabetes and hypertension, and osteogenesis imperfecta. Ranging from early-phase interventional studies (Phase 1 and Phase 1/Phase 2) to observational and unassigned classifications, these protocols are currently either actively recruiting or not yet recruiting participants. Trial sponsors include academic institutions, university health networks, government entities, and biotechnology companies such as Poseida Therapeutics and Roche-Genentech.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06045416	Not yet recruiting	Lyme Disease\|Borrelia Infections	University Children''s Hospital Zurich\|Institute of Medical Microbiology University of Zurich Zurich Switzerland	2024-04-01	--
NCT06003179	Not yet recruiting	Lymphoma Large B-Cell Diffuse	University Health Network Toronto	2024-04	Phase 1
NCT06014762	Recruiting	Diffuse Large B Cell Lymphoma\|Follicular Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Primary Mediastinal Large B-cell Lymphoma (PMBCL)\|Chronic Lymphocytic Leukemia	Poseida Therapeutics Inc.\|Roche-Genentech	2024-04	Phase 1
NCT06358859	Not yet recruiting	Cardiometabolic Risk Factors\|Diabetes\|High Blood Pressure\|Obesity\|Nutrition Security	Tufts University\|National Institute on Minority Health and Health Disparities (NIMHD)\|Tougaloo College Mississippi\|Delta Health Center Mississippi\|Reuben V. Anderson Center for Justice at Tougaloo	2024-04	Not Applicable
NCT05559801	Not yet recruiting	Osteogenesis Imperfecta\|Osteogenesis Imperfecta Type III	Emory University	2024-04	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Licochalcone D product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Licochalcone D directly inhibits the enzymatic activities of receptor tyrosine kinases including EGFR, c-Met, and JAK2, thereby suppressing downstream NF-κB p65 phosphorylation and triggering reactive oxygen species-dependent caspase activation and PARP cleavage. This targeted kinase inhibition disrupts downstream survival signaling to induce apoptotic cell death, underlying its therapeutic potential in malignant proliferative conditions such as diffuse large B-cell lymphoma evaluated in clinical studies.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).